{"entity":{"id":"mtx-241f","kind":"drug","name":"MTX-241F","aka":["MTX-241"],"tldr":"MTX-241F is an experimental small molecule from MEKanistic Therapeutics, in preclinical development for glioblastoma, diffuse intrinsic pontine glioma and brain metastases and other cancers.","summary":"MTX-241F (MTX-241) is a small molecule (brain-penetrant) from MEKanistic Therapeutics. A brain-penetrant dual PI3K and EGFR inhibitor. Its furthest stage is preclinical development, for glioblastoma, diffuse intrinsic pontine glioma, brain metastases and primary brain tumours. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"MEKanistic Therapeutics: mekanistic.com","url":"https://www.mekanistic.com/pipeline.html"},{"label":"MEKanistic Therapeutics: mekanistic.com","url":"https://www.mekanistic.com/pipeline.html"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["mekanistic-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MTX-241F","modality":"Small molecule (brain-penetrant)","mechanism":"A brain-penetrant dual PI3K and EGFR inhibitor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mtx-241f/","neighbours":{"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"mekanistic-therapeutics","kind":"company","name":"MEKanistic Therapeutics","route":"/companies/mekanistic-therapeutics/"}]}}